客家人群EGFR基因突变检测与非小细胞肺癌靶向用药及其预后的关系

The Relationship between the Detection of EGFR Gene Mutation in Hakka Population and the Targeted Medication of Non-small Cell Lung Cancer and Its Prognosis

目的探讨客家人群表皮生长因子受体(EGFR)基因突变检测与非小细胞肺癌(NSCLC)靶向用药及其预后的关系。方法于2016年1月—2019年11月期间,选取收治的客家人群NSCLC患者62例展开分析,所有入选对象均接受EGFR基因突变检测,分析EGFR基因图片情况与NSCLC靶向用药及其预后的关系。结果62例患者共检出EGFR基因突变型32例,其中19例为第19外显子缺失突变,13例为第21外显子L858R点突变,EGFR基因突变患者中腺癌患者较非腺癌患者更多,非吸烟患者较吸烟患者多,差异有统计学意义(P<0.05)。EGFR基因突变型患者的疾病控制率96.88%比EGFR野生型86.67%明显更高,中位无进展生存时间(7.22±2.86)个月比野生型患者(5.73±1.13)个月显著更长,差异有统计学意义(t=8.267、4.664,P<0.05)。结论客家人群NSCLC患者EGFR基因突变以第19外显子缺失突变为主,EGFR基因突变与肿瘤病理类型、吸烟史有关,EGFR基因突变检测对NSCLC靶向治疗有重要指导意义,有助于改善预后。

Objective To explore the relationship between the detection of epidermal growth factor receptor(EGFR)gene mutation in Hakka population and the targeted medication of non-small cell lung cancer(NSCLC)and its prognosis.Methods From January 2016 to November 2019,62 cases of NSCLC patients in the Hakka population were selected for analysis.All selected subjects were tested for EGFR gene mutations,and the relationship between EGFR gene pictures and NSCLC targeted drugs and their prognosis was analyzed.Results A total of 32 cases of EGFR gene mutations were detected in 62 patients,of which 19 cases were deletion mutations in exon 19 and 13 cases were point mutations in exon 21 in L858R.Among patients with EGFR gene mutations,adenocarcinoma patients were more than non-adenocarcinoma;more non-smokers than smokers,the difference was statistically significant(P<0.05).The disease control rate of patients with EGFR gene mutation was 96.88%,which was significantly higher than that of EGFR wild type,86.67%,and the median progression-free survival time(7.22±2.86)months was significantly longer than that of wild type patients(5.73±1.13)months.The difference was statistically significant(t=8.267,4.664,P<0.05).Conclusion The mutation of EGFR gene in NSCLC patients of Hakka population is mainly the mutation of exon 19 deletion.The mutation of EGFR gene is related to the tumor pathology type and smoking history.The detection of EGFR gene mutation has important guiding significance for NSCLC targeted therapy and helps to improve the prognosis.